(Q33397434)

26 July 2017

title

Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors (English)

1 reference

26 July 2017

Naomi Kiyota

9

0 references

author name string

Sachi Morita

1

1 reference

26 July 2017

Satoshi Oizumi

2

1 reference

26 July 2017

Hironobu Minami

3

1 reference

26 July 2017

Koichi Kitagawa

4

1 reference

26 July 2017

Yoshito Komatsu

5

1 reference

26 July 2017

Yutaka Fujiwara

6

1 reference

26 July 2017

Megumi Inada

7

1 reference

26 July 2017

Satoshi Yuki

8

1 reference

26 July 2017

Ayako Mitsuma

10

1 reference

26 July 2017

Masataka Sawaki

11

1 reference

26 July 2017

Hiromi Tanii

12

1 reference

26 July 2017

Junko Kimura

13

1 reference

26 July 2017

Yuichi Ando

14

1 reference

26 July 2017

publication date

1 October 2011

1 reference

Investigational New Drugs

26 July 2017

published in

1 reference

26 July 2017

volume

30

1 reference

26 July 2017

issue

5

1 reference

26 July 2017

page(s)

1950-1957

1 reference

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9751-0

Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9751-0

Histone deacetylase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9751-0

Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9751-0

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9751-0

Mechanisms of HDAC inhibitor-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9751-0

Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9751-0

A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9751-0

Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9751-0

Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9751-0

Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9751-0

EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9751-0

EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9751-0

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21964801

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21964801

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-011-9751-0

1 reference

Dimensions Publication ID

26 July 2017

1042427462

0 references

1 reference